Extended Data Fig. 3: The enhanced proximal crosslinking reactivity of iVAC accelerated PD-L1 degradation that promoted antigen presentation. | Nature

Extended Data Fig. 3: The enhanced proximal crosslinking reactivity of iVAC accelerated PD-L1 degradation that promoted antigen presentation.

From: Intratumoural vaccination via checkpoint degradation-coupled antigen presentation

Extended Data Fig. 3: The enhanced proximal crosslinking reactivity of iVAC accelerated PD-L1 degradation that promoted antigen presentation.The alternative text for this image may have been generated using AI.

a, SDS-PAGE and quantitative analysis of proximal crosslinking efficiency of GlueBody variants with distinct FnFSYs to PD-L1. Purified proteins (5 μM) were incubated with PD-L1 (0.5 μM) in PBS buffer at 37 °C for 30 min (n = 3 biological replicates). b, Time-course analysis of PD-L1 degradation in HCC2935 cells treated with GlueBody-CPP or GlueBody2-CPP (n = 3 biological replicates). c, Enhanced antigen presentation on hPD-L1/MC38 cells mediated by iVAC with optimized GlueBody (n = 3 biological replicates). d, Targeted PD-L1 degradation and antigen presentation induced by iVAC on hPD-L1/MC38 cells. e,f, iVAC shows comparable effects on (e) PD-L1 degradation in HCC2935 cells and (f) T cell activity restoration in a PD-1/PD-L1 functional assay (n = 3 biological replicates). Data are the mean ± s.d. Statistics: one-way ANOVA (a) and two-way ANOVA (b, c, e, f), each followed by Tukey’s multiple comparisons test. NS: not significant.

Source data

Back to article page